skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8102

Therapeutics and Clinical Risk Management

(2,215,707) Views

Editor in Chief Professor Garry Walsh

1178-203X

Original Research
Treating oligohydramnios with extract of Salvia miltiorrhiza: A randomized control trial
Hong-nü Chu, Mei-juan Shen
Therapeutics and Clinical Risk Management 2008, 4:287-290
05 March 2008

Original Research
Factors affecting therapeutic compliance: A review from the patient’s perspective
Jing Jin, Grant Edward Sklar, Vernon Min Sen Oh, Shu Chuen Li
Therapeutics and Clinical Risk Management 2008, 4:269-286
05 March 2008

Review
Zoledronic acid in the management of metastatic bone disease
Thomas J Polascik, Vladimir Mouraviev
Therapeutics and Clinical Risk Management 2008, 4:261-268
05 March 2008

Review
Cannabinoids in the management of difficult to treat pain
Ethan B Russo
Therapeutics and Clinical Risk Management 2008, 4:245-259
13 May 2008

Review
A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)
Lala M Dunbar, Derek M Tang, Robert M Manausa
Therapeutics and Clinical Risk Management 2008, 4:235-244
05 March 2008

Review
Management of laryngopharyngeal reflux with proton pump inhibitors
Christina Reimer, Peter Bytzer
Therapeutics and Clinical Risk Management 2008, 4:225-233
05 March 2008

Review
Therapeutical approach to plasma homocysteine and cardiovascular risk reduction
Marcello Ciaccio, Giulia Bivona, Chiara Bellia
Therapeutics and Clinical Risk Management 2008, 4:219-224
05 March 2008

Review
A review of topotecan in combination chemotherapy for advanced cervical cancer
Minoo Robati, David Holtz, Charles J Dunton
Therapeutics and Clinical Risk Management 2008, 4:213-218
05 March 2008

Review
Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
Ranjit K Goudar
Therapeutics and Clinical Risk Management 2008, 4:205-211
05 March 2008

Review
Long-term safety of aromatase inhibitors in the treatment of breast cancer
Jean-Marc A Nabholtz
Therapeutics and Clinical Risk Management 2008, 4:189-204
05 March 2008

Review
Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)
Martin Henkes, Heiko van der Kuip, Walter E Aulitzky
Therapeutics and Clinical Risk Management 2008, 4:163-187
05 March 2008

Review
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
Omar S Din, Penella J Woll
Therapeutics and Clinical Risk Management 2008, 4:149-162
05 March 2008

Review
Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris
Efstratios Vakirlis, Athanasios Kastanis, Demetrios Ioannides
Therapeutics and Clinical Risk Management 2008, 4:141-148
05 March 2008

Review
Contribution of capecitabine for therapy of patients with gastroesophageal cancer: an update of recent phase III results
Putao Cen, Eric D Tetzlaff, Jaffer A Ajani
Therapeutics and Clinical Risk Management 2008, 4:137-140
05 March 2008

Review
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
Teru Hideshima, Noopur Raje, Paul G Richardson, Kenneth C Anderson
Therapeutics and Clinical Risk Management 2008, 4:129-136
13 May 2008

Review
A review of solifenacin in the treatment of urinary incontinence
Ramandeep Basra, Con Kelleher
Therapeutics and Clinical Risk Management 2008, 4:117-128
05 March 2008

Review
Trabectedin and its potential in the treatment of soft tissue sarcoma
Philippe A Cassier, Armelle Dufresne, Jean-Yves Blay, Jérôme Fayette
Therapeutics and Clinical Risk Management 2008, 4:109-116
05 March 2008

Review
A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting
Mark A Ware, Paul Daeninck, Vincent Maida
Therapeutics and Clinical Risk Management 2008, 4:99-107
05 March 2008

Review
Advances in the use of topical imiquimod to treat dermatologic disorders
Francesco Lacarrubba, Maria Rita Nasca, Giuseppe Micali
Therapeutics and Clinical Risk Management 2008, 4:87-97
23 April 2008

Review
Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015
Robert A Bok
Therapeutics and Clinical Risk Management 2008, 4:79-85
05 March 2008

Review
Anidulafungin in the treatment of invasive fungal infections
Kathryn Sabol, Tawanda Gumbo
Therapeutics and Clinical Risk Management 2008, 4:71-78
05 March 2008

Review
A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil®)
Vandana A Govan
Therapeutics and Clinical Risk Management 2008, 4:65-70
05 March 2008

Review
Why does the world need another rotavirus vaccine?
Richard L Ward, Monica M McNeal, A Duncan Steele
Therapeutics and Clinical Risk Management 2008, 4:49-63
05 March 2008

Review
Serotonin receptor modulators in the treatment of irritable bowel syndrome
Mohammad Fayyaz, Jeffrey M Lackner
Therapeutics and Clinical Risk Management 2008, 4:41-48
05 March 2008

Review
Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review
Jason W Bennett, James S Lewis II, Michael W Ellis
Therapeutics and Clinical Risk Management 2008, 4:31-40
05 March 2008

Review
Critical appraisal of medical devices in the management of cerebrovascular disease
Michael J Schneck
Therapeutics and Clinical Risk Management 2008, 4:19-29
05 March 2008

Review
Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy
Mischel G Neill, Rohan Shahani, Alexandre R Zlotta
Therapeutics and Clinical Risk Management 2008, 4:11-18
05 March 2008

Review
Review of photodynamic therapy in actinic keratosis and basal cell carcinoma
Marica B Ericson, Ann-Marie Wennberg, Olle Larkö
Therapeutics and Clinical Risk Management 2008, 4:1-9
05 March 2008


Editorial ||FREE PAPER||
Garry M Walsh
Therapeutics and Clinical Risk Management 2008, 4:0-0
05 March 2008